Review



mst1  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Boster Bio mst1
    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and <t>MST1</t> levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Mst1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mst1/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    mst1 - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification"

    Article Title: Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2025.1579045

    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and MST1 levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Figure Legend Snippet: Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and MST1 levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.

    Techniques Used: Expressing, Biomarker Discovery, Transformation Assay, Protein Enrichment

    High serum levels of MST1 and APEH are associated with faster disease progression in MS patients in the validation sample. Multiple Sclerosis Severity Scores (MSSS) at the time of blood collection were analyzed in patients stratified into high and low abundance ratio (AR) groups for MST1 and APEH, using median cut-off values as the threshold.
    Figure Legend Snippet: High serum levels of MST1 and APEH are associated with faster disease progression in MS patients in the validation sample. Multiple Sclerosis Severity Scores (MSSS) at the time of blood collection were analyzed in patients stratified into high and low abundance ratio (AR) groups for MST1 and APEH, using median cut-off values as the threshold.

    Techniques Used: Biomarker Discovery



    Similar Products

    mst1  (Boster Bio)
    93
    Boster Bio mst1
    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and <t>MST1</t> levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Mst1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mst1/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    mst1 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    recombinant human msp  (R&D Systems)
    93
    R&D Systems recombinant human msp
    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and <t>MST1</t> levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Recombinant Human Msp, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human msp/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    recombinant human msp - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    human msp mst1 macrophage stimulating protein elisa kit picokinetm  (Boster Bio)
    93
    Boster Bio human msp mst1 macrophage stimulating protein elisa kit picokinetm
    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and <t>MST1</t> levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Human Msp Mst1 Macrophage Stimulating Protein Elisa Kit Picokinetm, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human msp mst1 macrophage stimulating protein elisa kit picokinetm/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    human msp mst1 macrophage stimulating protein elisa kit picokinetm - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    human msp protein  (Boster Bio)
    93
    Boster Bio human msp protein
    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and <t>MST1</t> levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.
    Human Msp Protein, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human msp protein/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    human msp protein - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and MST1 levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.

    Journal: Frontiers in Immunology

    Article Title: Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification

    doi: 10.3389/fimmu.2025.1579045

    Figure Lengend Snippet: Expression levels of six differentially abundant proteins in healthy controls (HC) and untreated multiple sclerosis (MS) patients in the validation sample. Protein expression levels were evaluated in a validation sample comprising HC, relapsing-onset MS (ROMS), and primary progressive MS (PPMS) groups. Initial comparisons across groups were performed using the Kruskal-Wallis test. When significant differences were observed, pairwise comparisons were conducted with a Bonferroni-adjusted alpha threshold ( P adj = 0.05). The results are presented as box plots: horizontal bars represent the median, while the box edges denote the 25 th –75 th percentiles. Whiskers extend to the 10 th and 90 th percentiles. Statistical analyses were conducted on untransformed data, with logarithmic transformation applied only to improve visualization of PRDX6 protein enrichment across groups. Further stratification of BST1 and MST1 levels among the three MS clinical forms and HC revealed that the observed differences in the ROMS group were primarily driven by the RRMS subgroup. * P adj <0.05; ** P adj <0.01: *** P adj <0.005; **** P adj ≤0.001.

    Article Snippet: The immunoassays were performed in serum samples by commercial enzyme linked immunosorbent assay (ELISA) kits: (Actinin-alpha 1 [ACTN1], N-Acylaminoacyl-Peptide Hydrolase [APEH], Bone Marrow Stromal Cell Antigen 1 [BST1], Complement Factor H-Related 2 [CFHR2], Complement Factor H-Related 5 [CFHR5], Elastase-Neutrophil Expressed [ELANE], Peroxiredoxin-6 [PRDX6], Brain phosphoglycerate Mutase 1 [PGAM1], S100 calcium-binding protein A6 [S100A6] and Fc fragment of IgG low affinity IIIa receptor [FCGR3A] (all of them from Antibodies-online, Aachen, Germany); Macrophage Stimulating 1-Hepatocyte Growth Factor Like [MST1] (from Boster Biological Technology, Pleasanton CA, USA) and Human Proprotein Convertase 9 [PCSK9] (from USA R&D Systems, Minneapolis, USA).

    Techniques: Expressing, Biomarker Discovery, Transformation Assay, Protein Enrichment

    High serum levels of MST1 and APEH are associated with faster disease progression in MS patients in the validation sample. Multiple Sclerosis Severity Scores (MSSS) at the time of blood collection were analyzed in patients stratified into high and low abundance ratio (AR) groups for MST1 and APEH, using median cut-off values as the threshold.

    Journal: Frontiers in Immunology

    Article Title: Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratification

    doi: 10.3389/fimmu.2025.1579045

    Figure Lengend Snippet: High serum levels of MST1 and APEH are associated with faster disease progression in MS patients in the validation sample. Multiple Sclerosis Severity Scores (MSSS) at the time of blood collection were analyzed in patients stratified into high and low abundance ratio (AR) groups for MST1 and APEH, using median cut-off values as the threshold.

    Article Snippet: The immunoassays were performed in serum samples by commercial enzyme linked immunosorbent assay (ELISA) kits: (Actinin-alpha 1 [ACTN1], N-Acylaminoacyl-Peptide Hydrolase [APEH], Bone Marrow Stromal Cell Antigen 1 [BST1], Complement Factor H-Related 2 [CFHR2], Complement Factor H-Related 5 [CFHR5], Elastase-Neutrophil Expressed [ELANE], Peroxiredoxin-6 [PRDX6], Brain phosphoglycerate Mutase 1 [PGAM1], S100 calcium-binding protein A6 [S100A6] and Fc fragment of IgG low affinity IIIa receptor [FCGR3A] (all of them from Antibodies-online, Aachen, Germany); Macrophage Stimulating 1-Hepatocyte Growth Factor Like [MST1] (from Boster Biological Technology, Pleasanton CA, USA) and Human Proprotein Convertase 9 [PCSK9] (from USA R&D Systems, Minneapolis, USA).

    Techniques: Biomarker Discovery